Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Oclusión puntual para el síndrome de ojo seco

Información

DOI:
https://doi.org/10.1002/14651858.CD006775.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 26 junio 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Salud ocular y de la visión

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Ann‐Margret Ervin

    Correspondencia a: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

    [email protected]

  • Andrew Law

    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

  • Andrew D Pucker

    Optometry & Vision Science, University of Alabama at Birmingham, Birmingham, USA

Contributions of authors

Review co‐ordination: AE, AL

Data collection for the review update

  • Designing search strategies: AE, RW, OS, CEV Trials Search Co‐ordinator

  • Undertaking searches: CEV Trials Search Co‐ordinator

  • Screening search results: AE, AL

  • Organizing retrieval of papers: AL

  • Screening retrieved papers against inclusion criteria: AE, AL

  • Appraising quality of papers: AE, AL

  • Extracting data from papers: AE, AL

  • Writing to authors of papers for additional information: AE

  • Providing additional data about papers: AE

  • Obtaining and screening data on unpublished studies: AE, AL

Data management for the review

  • Entering data into RevMan: AE, AL

  • Analyzing data: AE, AL

Interpretation of data

  • Providing a methodological perspective: AE, AL

  • Providing a clinical perspective: AP

  • Providing a policy perspective: AE, AP

  • Providing a consumer perspective: AE

Writing the review: AE, AL, AP
Providing general advice on the review: AE, AL, AP
Securing funding for the review: NA
Performing previous work that was the foundation of the current study: NA

Guarantor for review: AE

Sources of support

Internal sources

  • National Human Genome Research Institute Intramural funds, National Institutes of Health, USA.

    This research was supported in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health

External sources

  • Grant 1 U01 EY020522, National Eye Institute, National Institutes of Health, USA.

  • National Institute for Health Research (NIHR), UK.

    • Richard Wormald, Co‐ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV research sessions from the Department of Health through the award made by the NIHR to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.

    • This review was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base.

    The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

Declarations of interest

AE: none known.
AL: none known.
AP: none known.

Acknowledgements

The authors would like to thank Iris Gordon and Lori Rosman, Informationists for Cochrane Eyes and Vision (CEV), for designing the search strategy and conducting the electronic searches. We also acknowledge the CEV editorial team's support during the preparation of this review and thank Oliver Schein and Robert Wojciechowski for their contributions to the prior review published in 2010. We would like to also acknowledge Ke Chen, Xinyi Chen, and Shi‐ming Li for their help in screening full‐text reports, abstracting data, and translating Mandarin publications. Finally, we would like to thank our peer reviewers Jod Mehta and Barbara Hawkins.

Version history

Published

Title

Stage

Authors

Version

2017 Jun 26

Punctal occlusion for dry eye syndrome

Review

Ann‐Margret Ervin, Andrew Law, Andrew D Pucker

https://doi.org/10.1002/14651858.CD006775.pub3

2010 Sep 08

Punctal occlusion for dry eye syndrome

Review

Ann‐Margret Ervin, Robert Wojciechowski, Oliver Schein

https://doi.org/10.1002/14651858.CD006775.pub2

2007 Oct 17

Punctal occlusion for dry eye syndrome

Protocol

Ann‐Margret Ervin, Robert Wojciechowski, Oliver Schein

https://doi.org/10.1002/14651858.CD006775

Differences between protocol and review

Cochrane methodology regarding assessments of the risk of bias in included studies has changed, and the review authors updated the 'Assessment of risk of bias in included studies' section of the Methods to reflect these updated methodological. We also added methods for assessing the certainty of evidence using the GRADE approach and preparing 'Summary of findings' tables.

Data synthesis: We did not solely base our decision to perform meta‐analysis on the I2 statistic; we took statistical, methodological, and clinical heterogeneity into consideration.

We modified the follow‐up time points for our primary and secondary outcomes to two and four weeks. Two and four weeks were considered the clinically relevant time points for this review because this is when clinicians tend to schedule follow‐up visits for dry eye patients. We also chose these time points because two other systematic reviews (treatment of dry eye with over the counter artifical tears and treatment of dry eye with autologous serum) on dry eye used these time points when comparing similar dry eye outcomes (Pan 2013; Pucker 2016).

Keywords

MeSH

Medical Subject Headings Check Words

Female; Humans; Male;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Flow diagram.
Figuras y tablas -
Figure 1

Flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Punctal plug versus observation, Outcome 1 Symptomatic improvement at 1 month.
Figuras y tablas -
Analysis 1.1

Comparison 1 Punctal plug versus observation, Outcome 1 Symptomatic improvement at 1 month.

Comparison 1 Punctal plug versus observation, Outcome 2 Symptomatic improvement (long‐term).
Figuras y tablas -
Analysis 1.2

Comparison 1 Punctal plug versus observation, Outcome 2 Symptomatic improvement (long‐term).

Comparison 1 Punctal plug versus observation, Outcome 3 Ocular surface staining at 2 weeks.
Figuras y tablas -
Analysis 1.3

Comparison 1 Punctal plug versus observation, Outcome 3 Ocular surface staining at 2 weeks.

Comparison 1 Punctal plug versus observation, Outcome 4 Ocular surface staining at 1 month.
Figuras y tablas -
Analysis 1.4

Comparison 1 Punctal plug versus observation, Outcome 4 Ocular surface staining at 1 month.

Comparison 1 Punctal plug versus observation, Outcome 5 Ocular surface staining (long‐term).
Figuras y tablas -
Analysis 1.5

Comparison 1 Punctal plug versus observation, Outcome 5 Ocular surface staining (long‐term).

Comparison 1 Punctal plug versus observation, Outcome 6 Tear film stability at 1 month.
Figuras y tablas -
Analysis 1.6

Comparison 1 Punctal plug versus observation, Outcome 6 Tear film stability at 1 month.

Comparison 1 Punctal plug versus observation, Outcome 7 Tear film stability (long‐term).
Figuras y tablas -
Analysis 1.7

Comparison 1 Punctal plug versus observation, Outcome 7 Tear film stability (long‐term).

Comparison 1 Punctal plug versus observation, Outcome 8 Artificial tear use at 2 weeks.
Figuras y tablas -
Analysis 1.8

Comparison 1 Punctal plug versus observation, Outcome 8 Artificial tear use at 2 weeks.

Comparison 1 Punctal plug versus observation, Outcome 9 Artificial tear use at 1 month.
Figuras y tablas -
Analysis 1.9

Comparison 1 Punctal plug versus observation, Outcome 9 Artificial tear use at 1 month.

Comparison 1 Punctal plug versus observation, Outcome 10 Artificial tear use (long‐term).
Figuras y tablas -
Analysis 1.10

Comparison 1 Punctal plug versus observation, Outcome 10 Artificial tear use (long‐term).

Comparison 2 Punctal plugs versus cyclosporine, Outcome 1 Ocular surface staining at 1 month.
Figuras y tablas -
Analysis 2.1

Comparison 2 Punctal plugs versus cyclosporine, Outcome 1 Ocular surface staining at 1 month.

Comparison 2 Punctal plugs versus cyclosporine, Outcome 2 Ocular surface staining at 6 months.
Figuras y tablas -
Analysis 2.2

Comparison 2 Punctal plugs versus cyclosporine, Outcome 2 Ocular surface staining at 6 months.

Comparison 2 Punctal plugs versus cyclosporine, Outcome 3 Aqueous tear production at 1 month.
Figuras y tablas -
Analysis 2.3

Comparison 2 Punctal plugs versus cyclosporine, Outcome 3 Aqueous tear production at 1 month.

Comparison 2 Punctal plugs versus cyclosporine, Outcome 4 Aqueous tear production at 6 months.
Figuras y tablas -
Analysis 2.4

Comparison 2 Punctal plugs versus cyclosporine, Outcome 4 Aqueous tear production at 6 months.

Comparison 2 Punctal plugs versus cyclosporine, Outcome 5 Artificial tear use at 1 month.
Figuras y tablas -
Analysis 2.5

Comparison 2 Punctal plugs versus cyclosporine, Outcome 5 Artificial tear use at 1 month.

Comparison 2 Punctal plugs versus cyclosporine, Outcome 6 Artificial tear use at 6 months.
Figuras y tablas -
Analysis 2.6

Comparison 2 Punctal plugs versus cyclosporine, Outcome 6 Artificial tear use at 6 months.

Comparison 3 Punctal plugs versus oral pilocarpine, Outcome 1 Symptomatic improvement at 3 months.
Figuras y tablas -
Analysis 3.1

Comparison 3 Punctal plugs versus oral pilocarpine, Outcome 1 Symptomatic improvement at 3 months.

Comparison 3 Punctal plugs versus oral pilocarpine, Outcome 2 Ocular surface staining.
Figuras y tablas -
Analysis 3.2

Comparison 3 Punctal plugs versus oral pilocarpine, Outcome 2 Ocular surface staining.

Comparison 3 Punctal plugs versus oral pilocarpine, Outcome 3 Aqueous tear production.
Figuras y tablas -
Analysis 3.3

Comparison 3 Punctal plugs versus oral pilocarpine, Outcome 3 Aqueous tear production.

Comparison 4 Punctal plugs versus artificial tears, Outcome 1 Symptomatic improvement at 2 weeks.
Figuras y tablas -
Analysis 4.1

Comparison 4 Punctal plugs versus artificial tears, Outcome 1 Symptomatic improvement at 2 weeks.

Comparison 4 Punctal plugs versus artificial tears, Outcome 2 Symptomatic improvement at 3 months.
Figuras y tablas -
Analysis 4.2

Comparison 4 Punctal plugs versus artificial tears, Outcome 2 Symptomatic improvement at 3 months.

Comparison 4 Punctal plugs versus artificial tears, Outcome 3 Symptomatic improvement at 3 months.
Figuras y tablas -
Analysis 4.3

Comparison 4 Punctal plugs versus artificial tears, Outcome 3 Symptomatic improvement at 3 months.

Comparison 4 Punctal plugs versus artificial tears, Outcome 4 Ocular surface staining at 2 weeks.
Figuras y tablas -
Analysis 4.4

Comparison 4 Punctal plugs versus artificial tears, Outcome 4 Ocular surface staining at 2 weeks.

Comparison 4 Punctal plugs versus artificial tears, Outcome 5 Ocular surface staining at 3 months (Rose Bengal).
Figuras y tablas -
Analysis 4.5

Comparison 4 Punctal plugs versus artificial tears, Outcome 5 Ocular surface staining at 3 months (Rose Bengal).

Comparison 4 Punctal plugs versus artificial tears, Outcome 6 Ocular surface staining at 3 months (fluorescein).
Figuras y tablas -
Analysis 4.6

Comparison 4 Punctal plugs versus artificial tears, Outcome 6 Ocular surface staining at 3 months (fluorescein).

Comparison 4 Punctal plugs versus artificial tears, Outcome 7 Aqueous tear production at 2 weeks.
Figuras y tablas -
Analysis 4.7

Comparison 4 Punctal plugs versus artificial tears, Outcome 7 Aqueous tear production at 2 weeks.

Comparison 4 Punctal plugs versus artificial tears, Outcome 8 Aqueous tear production at 3 months.
Figuras y tablas -
Analysis 4.8

Comparison 4 Punctal plugs versus artificial tears, Outcome 8 Aqueous tear production at 3 months.

Comparison 4 Punctal plugs versus artificial tears, Outcome 9 Aqueous tear production at 3 months.
Figuras y tablas -
Analysis 4.9

Comparison 4 Punctal plugs versus artificial tears, Outcome 9 Aqueous tear production at 3 months.

Comparison 4 Punctal plugs versus artificial tears, Outcome 10 Tear film stability at 2 weeks.
Figuras y tablas -
Analysis 4.10

Comparison 4 Punctal plugs versus artificial tears, Outcome 10 Tear film stability at 2 weeks.

Comparison 4 Punctal plugs versus artificial tears, Outcome 11 Tear film stability at 3 months.
Figuras y tablas -
Analysis 4.11

Comparison 4 Punctal plugs versus artificial tears, Outcome 11 Tear film stability at 3 months.

Comparison 4 Punctal plugs versus artificial tears, Outcome 12 Punctate epithelial keratopathy.
Figuras y tablas -
Analysis 4.12

Comparison 4 Punctal plugs versus artificial tears, Outcome 12 Punctate epithelial keratopathy.

Comparison 5 Punctal plugs in the upper versus lower puncta, Outcome 1 Symptomatic improvement at 1 month.
Figuras y tablas -
Analysis 5.1

Comparison 5 Punctal plugs in the upper versus lower puncta, Outcome 1 Symptomatic improvement at 1 month.

Comparison 5 Punctal plugs in the upper versus lower puncta, Outcome 2 Aqueous tear production at 1 month.
Figuras y tablas -
Analysis 5.2

Comparison 5 Punctal plugs in the upper versus lower puncta, Outcome 2 Aqueous tear production at 1 month.

Comparison 5 Punctal plugs in the upper versus lower puncta, Outcome 3 Tear film stability at 1 month.
Figuras y tablas -
Analysis 5.3

Comparison 5 Punctal plugs in the upper versus lower puncta, Outcome 3 Tear film stability at 1 month.

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 1 Symptomatic improvement at 11 weeks.
Figuras y tablas -
Analysis 6.1

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 1 Symptomatic improvement at 11 weeks.

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 2 Ocular surface staining at 11 weeks.
Figuras y tablas -
Analysis 6.2

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 2 Ocular surface staining at 11 weeks.

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 3 Aqueous tear production at 11 weeks.
Figuras y tablas -
Analysis 6.3

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 3 Aqueous tear production at 11 weeks.

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 4 Tear film stability at 11 weeks.
Figuras y tablas -
Analysis 6.4

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 4 Tear film stability at 11 weeks.

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 5 Artificial tear use at 11 weeks.
Figuras y tablas -
Analysis 6.5

Comparison 6 Acrylic punctal plugs versus silicone punctal plugs, Outcome 5 Artificial tear use at 11 weeks.

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 1 Symptomatic improvement (long‐term).
Figuras y tablas -
Analysis 7.1

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 1 Symptomatic improvement (long‐term).

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 2 Ocular surface staining (long‐term).
Figuras y tablas -
Analysis 7.2

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 2 Ocular surface staining (long‐term).

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 3 Aqueous tear production (long‐term).
Figuras y tablas -
Analysis 7.3

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 3 Aqueous tear production (long‐term).

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 4 Tear film stability (long‐term).
Figuras y tablas -
Analysis 7.4

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 4 Tear film stability (long‐term).

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 5 Artificial tear use (long‐term).
Figuras y tablas -
Analysis 7.5

Comparison 7 Intracanalicular plugs versus silicone punctal plugs, Outcome 5 Artificial tear use (long‐term).

Summary of findings for the main comparison. Summary of findings: punctal plugs versus no punctal plugs

Punctal plugs compared with no punctal plugs for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: silicone or collagen punctal plugs

Comparison: no punctal plugs (observation or sham treatment)

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

No punctal plugs

Punctal plugs

Symptomatic improvement

Follow‐up: long‐term*

A lower score favors punctal plugs

See comments

See comments

89

(2 RCT)

⊕⊝⊝⊝
Very lowa,b

Mansour 2007 reported little or no difference in Ocular and Oral Symptoms score, which ranged from 0 to 10 points (MD ‐0.46 points, 95% CI ‐1.24 to 0.32; eyes = 26).

Nava‐Castaneda 2003 reported a slight decrease in symptom score, assumed to range from 0 to 105 points, but it does not seem to be clinically important (MD ‐2.62 points, 95% CI ‐3.32 to ‐1.93; eyes = 61).

Yung 2012 reported little or no difference in dry eye symptom score, ranging from 0 to 3 points (MD ‐0.75 points, 95% CI ‐1.53 to 0.02; eyes = 28)

Ocular surface staining

Follow‐up: long‐term*

A higher value is less advantageous

Both Rose Bengal and fluorescein staining scores ranged from 0 to 4, where 0 represented no staining and 4 represented heavy staining

The mean fluorescein staining score was 1.70

MD 1.50 lower than observation group

(1.88 to 1.12 lower (better) than observation group)

61

(1 RCT)

⊕⊕⊝⊝
Lowc,d

Aqueous tear production

Follow‐up: long‐term*

A higher value is more advantageous

See comments

See comments

28

(1 RCT)

⊕⊕⊝⊝
Lowc,d

Yung 2012 did not provide quantitative data, but reported that "Schirmer values tended to increase in the plug group after plug insertion; however, the changes did not reach significance"

Tear film stability

Follow‐up: 6 months

A higher value is more advantageous

The mean tear film stability was 2.34 seconds

MD 1.93 seconds longer than observation group

(0.67 to 3.20 seconds longer (better) than observation group)

28

(1 RCT)

⊕⊕⊝⊝
Lowa,b

Artificial tear use

Follow‐up: long‐term*

Fewer applications favors punctal plugs

The mean number of applications was 3.6 applications

MD 2.70 fewer applications than observation group

(3.11 to 2.29 fewer applications than observation group)

61

(1 RCT)

⊕⊕⊝⊝
Lowe

Adverse events

Follow‐up: end of study

See comments

See comments

146
(4 RCT)

⊕⊝⊝⊝
Very lowf,g

Slusser 1998: all adverse events occurred in the punctal plug group, reported 23/28 participants had epiphora, 3/28 participants reported itching in area of plug placement, 1/28 participants had tenderness and swelling of lids with mucous discharge.

Spontaneous plug loss occurred in 6/20 eyes with silicone punctal plugs in the Mansour 2007.

One or 31 participants receiving collagen and silicone punctal plugs experienced epiphora in the Nava‐Castaneda 2003 study.

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SMD: standardized mean difference; RCT: randomized controlled trial.

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded two levels for methodological heterogeneity.
bDowngraded one level for high risk of detection and attrition bias.

cDowngraded one level for imprecision as indirectness of evidence because the confidence interval was either wide or clinically not important.

dDowngraded one level for high risk of attrition bias.

eDowngraded two levels for high risk of performance, detection, and attrition bias.

fDowngraded two levels for attrition bias.

gDowngraded one level for sparse and inconsistent data, particularly with respect to epiphora.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings for the main comparison. Summary of findings: punctal plugs versus no punctal plugs
Summary of findings 2. Summary of findings: punctal plugs versus cyclosporine

Punctal plugs compared with cyclosporine for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: punctal plugs

Comparison: cyclosporine

Outcomes

Illustrative comparative risks* (95% CI)

No of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Cyclosporine

Punctal plugs

Symptomatic improvement

Study investigators did not report this outcome at 2 weeks, 1 month, or long‐term.

Ocular surface staining

Follow‐up: 6 months

Any value greater than zero is abnormal

Range: 0 to 4 points; 0 = no staining, 1 = staining of the nasal conjunctiva only, 2 = staining of both the nasal and temporal conjunctiva, 3 = peripheral corneal staining, 4 = central corneal staining

See comments

See comments

20

(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The study investigators of Roberts 2007 stated: "there was greater improvement in conjunctival staining with cyclosporine or the combination than with plugs alone." It was unclear whether Rose Bengal or fluorescein staining was used. Also,

the study investigators did not specify the time point and so we assumed that their statement applies for 1, 3, and 6 months follow‐up.

Aqueous tear production

Follow‐up: 6 months

A higher value is more advantageous

The mean change in aqueous tear production was 1.5 mm/3 min lower than baseline

MD 0.80 mm/3 min higher than cyclosporine group

(0.74 lower (better) to 2.34 higher (worse) than cyclosporine group)

20
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The study investigators of Roberts 2007 stated: "There was a greater increase in Schirmer score with plugs, either alone or in combination with cyclosporine." The study investigators did not specify the for which time point and so we assumed that their statement applies for 1, 3, and 6 months follow‐up.

Tear film stability

Follow‐up: 6 months

Study investigators did not report this outcome at 2 weeks, 1 month, or long‐term.

Artificial tear use

Follow‐up: 6 months

range: 1‐5 applications

Fewer applications favors punctal plugs

The mean change in number of applications from baseline was 3.2 more applications than baseline

MD 1.10 applications more than baseline

(0.04 fewer to 2.24 more applications than cyclosporine group)

20
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The study investigators of Roberts 2007 stated: "decreased frequency of artificial tears was greatest for combination therapy and least for punctal plugs." The study investigators did not specify the for which time point and so we assumed that their statement applies for 1, 3, and 6 months follow‐up.

Adverse events

Follow‐up: end of study

See comments

See comments

22
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Roberts 2007 reported 1/11 participants experienced plug displacement in the plug group, while 1/11 participants experienced a burning sensation in the cyclosporine group.

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial.

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded one level for imprecision of results (wide confidence intervals).

bDowngraded two levels for high risk of detection, performance, attrition, and other bias.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 2. Summary of findings: punctal plugs versus cyclosporine
Summary of findings 3. Summary of findings: punctal plugs versus oral pilocarpine

Punctal plugs compared with oral pilocarpine for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: punctal plugs

Comparison: oral pilocarpine

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of eyes
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Oral pilocarpine

Punctal plugs

Symptomatic improvement

Follow‐up: 3 months

The study investigators defined improvements in subjective ocular symptoms as an improvement of >55 mm for responses to the eye questionnaire on a 100 mm visual analog scale.

A RR less than one favors punctal plugs.

897 per 1000

619 per 1000

(439 to 852)

RR 0.69

(0.49 to 0.95)

55
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Ocular surface staining

Follow‐up: 3 months

A higher value is less advantageous

Range: van Bijsterveld schema, which is on a scale of 0 to 9 points

The mean change in Rose Bengal staining score was 1.00 lower (better) than baseline in the right eye

MD 0.10 higher (worse) than oral pilocarpine group

(0.56 lower (better) to 0.76 higher (worse) than oral pilocarpine group)

55
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The mean change in Rose Bengal staining score was 1.10 lower (better) than baseline in the left eye

MD 0.60 higher (worse) than oral pilocarpine group

(0.10 to 1.10 higher (worse) than oral pilocarpine group)

55
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Aqueous tear production

Follow‐up: 3 months

A higher value more advantageous

The mean change in aqueous tear production was 0.30 mm/5 min higher (better) than baseline in the right eye

MD 0.10 mm/5 min lower (worse) than oral pilocarpine group

(0.53 mm/5 min lower (worse) to 0.33 mm/5 min higher (better) than oral pilocarpine group)

55
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The mean change in aqueous tear production was 1.2 mm/5 min higher (better) than baseline in the left eye

MD 0.50 mm/5 min lower (worse) than oral pilocarpine group

(1.06 mm/5 min lower (worse) to 0.06 mm/5 min higher (better) than oral pilocarpine group)

55
(1 RCT)

Tear film stability

Study investigators did not report this outcome.

Artificial tear use

Study investigators did not report this outcome.

Adverse events

Follow‐up: 3 months

See comments

See comments

55
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Tsifetaki 2003 reported: "commonly reported adverse events were headache, increased sweating,nausea, and vomiting in the pilocarpine group, while 1 patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study." pg 1204

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded two levels for high risk of performance and detection bias as the participant and outcome assessors were not masked to the treatment groups and the self‐reported symptomatic improvement might be biased.
bDowngraded one level for imprecision as the confidence interval is either wide or clinically not important.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 3. Summary of findings: punctal plugs versus oral pilocarpine
Summary of findings 4. Summary of findings: punctal plugs versus artificial tears

Punctal plugs compared with artificial tears for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: punctal plugs

Comparison: artificial tears

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of eyes
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Artificial tears

Punctal plugs

Symptomatic improvement

Follow‐up: 3 months

The study investigators defined improvements in subjective ocular symptoms as an improvement of >55 mm for responses to the eye questionnaire on a 100 mm visual analog scale.

A RR greater than one favors punctal plugs.

Both studies used different symptomatic improvement score; one study used the Ocular Surface Disease Index that ranged from 0 points = never to 4 points = all the time. The second study use the sum of scores for dryness, foreign body sensation, and visual fatigue; each score had a different range, but a higher score corresponded to more symptoms.

286 per 1000

654 per 1000

(343 to 1000)

RR 2.29

(1.2 to 4.38)

54

(1 RCT)

⊕⊝⊝⊝
Very lowa,b,c

The mean symptomatic improvement score ranged from 15.9 to 26.92

SMD 0.88 lower (better) than artificial tears group

(1.24 to 0.51 lower (better) than artificial tears group)

130

(2 RCTs)

Ocular surface staining

Follow‐up: 3 months

Range: 0 = absent; 1 = trace; 2 = mild; 3 = moderate; 4 =

severe

A higher value is worse

The mean change in Rose Bengal staining score was 1.0 point lower (better) than baseline in the right eye

MD 0.10 points higher (worse) than artificial tears group

(0.56 lower (better) to 0.76 higher (worse) than artificial tears group)

55
(1 RCT)

⊕⊕⊝⊝
Lowd

The mean change in Rose Bengal staining score was 1.1 lower (better) than baseline in the left eye

MD 0.60 points higher (worse) than artificial tears group

(0.10 to 1.10 higher (worse) than artificial tears group)

55
(1 RCT)

Aqueous tear production

Follow‐up: long‐term*

A higher value is more advantageous

The mean change in aqueous tear production was 0.2 mm/5 min higher (better) than baseline in the right eye

MD 0.00 mm/5 min higher (better) than artificial tears group

(0.33 mm/5 min lower (worst) to 0.33 mm/5 min higher (better) than artificial tears group)

54
(1 RCT)

⊕⊕⊝⊝
Lowc,e

The mean change in aqueous tear production was 0.6 mm/5 min higher (better) than baseline in the left eye

MD 0.10 mm/5 min higher (better) than artificial tears group

(0.35 mm/5 min lower (worst) to 0.55 mm/5 min higher (better) than artificial tears group)

54
(1 RCT)

The mean aqueous tear production ranged from 4.89 to 8.95 mm/ 5 min

MD 2.16 mm/ 5 min higher (better)

(1.41 to 2.90 mm/ 5 min higher (better) than artificial tears group)

130

(2 RCTs)

Tear film stability

Follow‐up: long‐term*

A higher value is more advantageous

The mean tear film stability ranged from 3.24 to 6 seconds

MD 1.02 seconds longer (better) than artificial tears group

(0.60 to 1.44 seconds longer (better) than artificial tears group)

130
(2 RCT)

⊕⊕⊕⊝
Moderatec

Artificial tear use

Outcome not relevant to this comparison

Adverse events (punctate epithelial keratopathy)

Follow‐up: end of study

375 per 1000

499 per 1000

(214 to 1000)

RR 1.33 (0.57 to 3.12)

54
(1 RCT)

⊕⊕⊝⊝
Lowa,c

Tsifetaki 2003 reported: "four patients had mild headache, of whom three also presented with nausea, vomiting, and sweating" (p 1205) and "one patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study" (p 1204)

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded two levels for high risk of performance and detection bias as participants and outcome assessors were unmasked to the assigned treatment group and might influence the self‐reported symptomatic improvement.
bDowngraded one level for high unexplained statistical heterogeneity or inconsistent results.
cDowngraded one level for imprecision of results as the confidence interval was either wide or clinically not important.
dDowngraded two levels for imprecision of results as the confidence interval was wide and clinically not important.
eDowngraded for inconsistent results.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 4. Summary of findings: punctal plugs versus artificial tears
Summary of findings 5. Summary of findings: punctal plugs in the upper versus lower puncta

Punctal plugs occluded in the upper puncta compared with the lower puncta for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: punctal plugs occluded in the upper puncta

Comparison: punctal plugs occluded in the lower puncta

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of eyes
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower puncta

Upper puncta

Symptomatic improvement

Follow‐up: long‐term*

Study investigators did not report this outcome.

Ocular surface staining

Follow‐up: long‐term*

Study investigators did not report this outcome.

Aqueous tear production

Follow‐up: long‐term*

Study investigators did not report this outcome.

Tear film stability

Follow‐up: long‐term*

Study investigators did not report this outcome.

Artificial tear use

Study investigators did not report this outcome.

Adverse events

See comments

See comments

See comments

40
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Chen 2010 reported "no complication was observed in dry eye patients or control subjects during the period of this study." It is unclear which complications were collected.

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded one level for potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias.
bDowngraded one level for imprecision of results as the confidence interval was wide.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 5. Summary of findings: punctal plugs in the upper versus lower puncta
Summary of findings 6. Summary of findings: acrylic versus silicone punctal plugs

Acrylic punctal plugs compared with silicone punctal plugs for dry eye syndrome

Patient or population: mostly women with dry eye syndrome

Settings: eye clinics

Intervention: acrylic punctal plugs

Comparison: silicone punctal plugs

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of eyes
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Silicone punctal plugs

Acrylic punctal plugs

Symptomatic improvement

Follow‐up: 11 weeks

Range: 0 to 70 points

A visual analog scales 10 cm in length for seven symptoms: dryness, grittiness, foreign body sensation, pain, stinging, burning, and itching was used.

A lower score favors acrylic punctal plugs

The mean symptomatic improvement score was 21.9 points

MD 0.90 points higher than silicone punctal plug group

(6.94 points lower than silicone punctal plug group to 8.74 points higher than silicone punctal plug group)

36
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Ocular surface staining

Follow‐up: 11 weeks

A higher value is less advantageous

Range: 0 to 3 points

The mean fluorescein staining score was 1.63 points

MD 0.43 points higher (worst) than silicone punctal plug group

(1.61 lower (better) than silicone punctal plug group to 2.47 higher (worse) than silicone punctal plug group)

36
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The mean Rose Bengal staining score was 0.55 points

MD 0.45 points higher (worst) than silicone punctal plug group

(0.09 lower (better) than silicone punctal plug group to 0.99 higher (worst) than silicone punctal plug group)

Aqueous tear production

Follow‐up: 11 weeks

A higher value is more advantageous

The mean aqueous tear production was 3.8 mm/5 min

MD 1.07 mm/5 min higher than silicone punctal plug group

(1.62 lower than silicone punctal plug group to 3.76 higher than silicone punctal plug group)

36
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Authors did not report the time interval in which the Schirmer's test 1 without anesthesia was performed. We assumed it was done over 5 minutes.

Tear film stability

Follow‐up: 11 weeks

A higher value is more advantageous

The mean tear film stability was 3.5 seconds

MD 0.36 seconds longer than silicone punctal plug group

(1.22 seconds shorter than silicone punctal plug group to 1.94 longer than silicone punctal plug group)

36
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Artificial tear use

Follow‐up: 11 weeks

Range: 1‐5 applications

Fewer applications favors punctal plugs

The mean number of applications was 4.67 applications

MD 0.11 more applications than silicone punctal plug group

(2.32 fewer applications than silicone punctal plug group to 2.54 more applications than silicone punctal plug group)

36
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Adverse events

Follow‐up: 11 weeks

See comments

See comments

36
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

1 acrylic punctal plug participant experienced epiphora, 1 silicone punctal plug participant experienced intermittent ocular irritation, and 2 silicone and 1 acrylic punctal plug participants experienced temporary foreign body sensation.

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial.

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded two levels for imprecision of results (wide confidence intervals).

bDowngraded one level for risk of bias as selection, attrition and reporting bias were judged to be unclear.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 6. Summary of findings: acrylic versus silicone punctal plugs
Summary of findings 7. Summary of findings: intracanalicular versus silicone punctal plugs

Intracanalicular punctal plugs compared with silicone punctal plugs for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: intracanalicular punctal plugs

Comparison: silicone punctal plugs

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of eyes
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Silicone punctal plugs

Intracanalicular punctal plugs

Symptomatic improvement

Follow‐up: 3 months

Subjective dry eye symptoms for each eye was reported; investigators measured soreness, scratching, grittiness, dryness and/or burning using a 100 mm visual analog scale (VAS; 0 mm = no symptoms, 100 mm = maximum intensity)

The mean symptomatic improvement was 38.5 points

The mean difference in symptomatic improvement was 3.10 points lower (14.97 lower to 8.77 higher)

57
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Ocular surface staining

Follow‐up: 3 months

A higher value is less advantageous

Range: 0 to 3 points; 0 = no staining and 3 = most intense staining

The mean Rose Bengal staining score was 3.0

MD 0.20 higher than observation group

(0.71 lower to 1.11 higher than silicone punctal plugs group)

57
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

The mean fluorescein staining score was 0.7 points

MD 0.40 points higher than observation group

(0.04 lower to 0.84 higher than silicone punctal plugs group)

57
(1 RCT)

Aqueous tear production

Follow‐up: 3 months

Study investigators did not report this outcome.

Tear film stability

Follow‐up: 3 months

Study investigators did not report this outcome.

Artificial tear use

Follow‐up: 3 months

Fewer applications favors intracanalicular plugs

The mean artificial tear use was 6.4

MD 1.30 fewer applications

(4.04 fewer to 1.44 more applications)

57
(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Adverse events

Study investigators did not report on adverse events.

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded two levels for imprecision of results (wide confidence intervals).
bDowngraded one level for high risk of attrition bias.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 7. Summary of findings: intracanalicular versus silicone punctal plugs
Summary of findings 8. Summary of findings: collagen versus silicone punctal plugs

Collagen punctal plugs compared with silicone punctal plugs for dry eye syndrome

Patient or population: adults with dry eye syndrome

Settings: eye clinics

Intervention: collagen punctal plugs

Comparison: silicone punctal plugs

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of eyes
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Silicone punctal plugs

Collagen punctal plugs

Symptomatic improvement

Follow‐up: 3 months

The Canadian Dry Eye Assessment range from 0 to 48 points; where less than 5 points was normal, 5 to 15 points was mild, 20 to 25 points was moderate, 30 to 48 points was severe.

The mean symptomatic improvement score was 0.25 points

MD 0.81 higher than silicone punctal group

(2.94 lower to 4.56 higher than silicone punctal group)

50

(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Ocular surface staining

Follow‐up: 3 months

Range: 0 to 15 points

A higher value is less advantageous

The mean fluorescein stain score was 2.00

MD 0.76 lower than silicone punctal group

(18.5 lower to 17.0 higher than silicone punctal group)

50

(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Aqueous tear production

Follow‐up: 3 months

A higher value is more advantageous

The mean aqueous tear production was 16.89 mm/5 min

MD 0.67 mm/5 min higher than silicone punctal group

(17.28 lower to 18.62 higher than silicone punctal group)

50

(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Authors did not report the time interval in which the Schirmer's test 1 without anesthesia was performed. We assumed it was done over 5 minutes.

Tear film stability

Follow‐up: 3 months

A higher value is more advantageous

The mean tear film stability was 4.67 seconds

MD 0.21 seconds higher than silicone punctal group
(1.81 lower to 2.23 higher than silicone punctal group)

50

(1 RCT)

⊕⊝⊝⊝
Very lowa,b

Artificial tear use

Follow‐up: 3 months

Fewer applications favors collagen punctal plugs

The mean number of artificial tear applications was 1.34 applications

MD 0.06 fewer applications

(0.23 fewer to 0.12 more applications than silicone punctal group)

50

(1 RCT)

⊕⊕⊝⊝
Lowa

Adverse events

Follow‐up: end of study

See comments

See comments

See comments

98

(2 RCT)

⊕⊝⊝⊝
Very lowa,b

Both studies reported that none of the participants developed adverse events or complications related to punctal plugs.

*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; RCT: randomized controlled trial.

GRADE Working Group grades of evidence
High‐certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate‐certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low‐certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low‐certainty: we are very uncertain about the estimate.

aDowngraded two levels for imprecision of results as the confidence interval was wide and clinically not important.

bDowngraded one level for risk of bias as risk of bias as we judged selection, performance, detection, attrition, and reporting bias to be unclear.

*We defined long‐term follow‐up as between two months and one year.

Figuras y tablas -
Summary of findings 8. Summary of findings: collagen versus silicone punctal plugs
Table 1. Comparisons

1. Punctal plugs versus observation.

Lowther 1995

Collagen intracanalicular plugs were inserted in the upper and lower puncta

Sham treatment

Mansour 2007

Silicone punctal plugs

No occlusion

Nava‐Castaneda 2003

Collagen plus silicone punctal plugs

Sham treatment

Roberts 2007

Bilateral collagen punctal plugs in the lower lids + cyclosporine eye drops to both eyes twice daily

Cyclosporine ophthalmic emulsion 0.05%

Slusser 1998

Silicone punctal plugs in the upper and lower puncta

Sham treatment

Yung 2012

Silicone punctal plugs

Observation

2. Punctal plugs versus cyclosporine.

Roberts 2007

Bilateral collagen punctal plugs in the lower lids only

Cyclosporine ophthalmic emulsion 0.05%

3. Punctal plugs versus oral pilocarpine.

Tsifetaki 2003

Collagen punctal plugs

Oral pilocarpine

4. Punctal plugs versus artificial tears.

Feng 2011

Collagen punctal plugs

Artificial tears

Qiu 2012

Acrylic punctal plugs

Artificial tears

Qiu 2013

Acrylic punctal plugs

Artificial tears

Tsifetaki 2003

Collagen punctal plugs

Artificial tears

Zhou 2016

Thermal Memory hydrophobic acrylic polymer rigid rod punctal plug

Artificial tears

5. Punctal plugs in the lower puncta versus the upper puncta.

Chen 2010

Collagen punctal plugs in the lower puncta

Collagen punctal plugs in the upper puncta

Farrell 2003

Collagen punctal plugs in the lower puncta

Collagen punctal plugs in the lower and upper puncta

Kaido 2012

Silcone punctal plugs in the lower puncta

Silcone punctal plugs in the upper puncta

6. Acrylic punctal plugs versus silicone punctal plugs.

Burgess 2008

Acrylic punctal plugs

Silicone punctal plugs

7. Intracanalicular plugs versus Silicone punctal plugs.

Rabensteiner 2013

Intracanicular

Silicone punctal plugs

8. Collagen punctal plugs versus silicone punctal plugs.

Altan‐Yaycioglu 2005

Collagen punctal plugs

Silicone punctal plugs

Brissette 2015

Collagen punctal plugs were inserted in the lower punctum

Silicone punctal plugs were inserted in the lower punctum

Excluded comparisons

Tsifetaki 2003

Artificial tears

Oral pilocarpine

Figuras y tablas -
Table 1. Comparisons
Comparison 1. Punctal plug versus observation

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Symptomatic improvement at 1 month Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Symptomatic improvement (long‐term) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3 Ocular surface staining at 2 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

4 Ocular surface staining at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5 Ocular surface staining (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

6 Tear film stability at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

7 Tear film stability (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

8 Artificial tear use at 2 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

9 Artificial tear use at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10 Artificial tear use (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 1. Punctal plug versus observation
Comparison 2. Punctal plugs versus cyclosporine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Ocular surface staining at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Ocular surface staining at 6 months Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3 Aqueous tear production at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

4 Aqueous tear production at 6 months Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5 Artificial tear use at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

6 Artificial tear use at 6 months Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 2. Punctal plugs versus cyclosporine
Comparison 3. Punctal plugs versus oral pilocarpine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Symptomatic improvement at 3 months Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Ocular surface staining Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2.1 Right eye

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Left eye

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Aqueous tear production Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 Right eye

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Left eye

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 3. Punctal plugs versus oral pilocarpine
Comparison 4. Punctal plugs versus artificial tears

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Symptomatic improvement at 2 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Symptomatic improvement at 3 months Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3 Symptomatic improvement at 3 months Show forest plot

2

130

Mean Difference (IV, Fixed, 95% CI)

‐4.20 [‐5.87, ‐2.53]

4 Ocular surface staining at 2 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5 Ocular surface staining at 3 months (Rose Bengal) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5.1 Right eye

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Left eye

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Ocular surface staining at 3 months (fluorescein) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

7 Aqueous tear production at 2 weeks Show forest plot

2

82

Mean Difference (IV, Fixed, 95% CI)

0.83 [‐1.05, 2.71]

8 Aqueous tear production at 3 months Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

8.1 Right

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Left

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Aqueous tear production at 3 months Show forest plot

2

130

Mean Difference (IV, Fixed, 95% CI)

2.16 [1.41, 2.90]

10 Tear film stability at 2 weeks Show forest plot

2

82

Mean Difference (IV, Fixed, 95% CI)

0.26 [‐0.57, 1.09]

11 Tear film stability at 3 months Show forest plot

2

130

Mean Difference (IV, Fixed, 95% CI)

1.02 [0.60, 1.44]

12 Punctate epithelial keratopathy Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 4. Punctal plugs versus artificial tears
Comparison 5. Punctal plugs in the upper versus lower puncta

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Symptomatic improvement at 1 month Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Aqueous tear production at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3 Tear film stability at 1 month Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 5. Punctal plugs in the upper versus lower puncta
Comparison 6. Acrylic punctal plugs versus silicone punctal plugs

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Symptomatic improvement at 11 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Ocular surface staining at 11 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2.1 Rose Bengal

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Fluorescein

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Aqueous tear production at 11 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

4 Tear film stability at 11 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5 Artificial tear use at 11 weeks Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 6. Acrylic punctal plugs versus silicone punctal plugs
Comparison 7. Intracanalicular plugs versus silicone punctal plugs

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Symptomatic improvement (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Ocular surface staining (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2.1 Rose Bengal

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Fluorescein

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Aqueous tear production (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 Schirmer test I without anesthesia

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Tear film stability (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5 Artificial tear use (long‐term) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 7. Intracanalicular plugs versus silicone punctal plugs